Hyundai Bioscience is getting closer to its Antiviral, XAFTY trial process succession

Introduction

Hyundai Bioscience, a well-known biotechnology company highly focused on establishing novel drug delivery systems (DDS) to advance and contribute to the existing drugs to spot precision in new therapeutic applications. Company been a member of the US Medical CBRN Defence Consortium (MCDC), has this opportunity to get closer support and advice from MCDC to excel in its development.

With its comprehensive drug delivery systems, Hyundai leads in the various markets and retains its position as a safe and effective company to restructure the overall presence of the existing drugs.

Announcement

Hyundai Bioscience uncovered a new direction and weapon to oppose viral epidemics with its latest proud news of starting with the Phase 2 clinical trials in the United States. Alongside, the company also presented insight into its pre-emptive therapeutic strategy by implementing Xafty™. This screening spotted a unique transformation recording from the completion in Vietnam to the new start in America.

The heart of this announcement was centralized to the clinical strategy in partnership with the Professor of Medicine and Assistant Vice Chancellor at the University of California, San Diego (UCSD), Dr Davey Smith. Mr Smith is the one who supervised the U.S. government’s ACTIV-2 COVID-19 trials and also helped the U.S. healthcare sector, largely with its excellence in diagnosing the three aggressive variants simultaneously, confirming no integrated countermeasure.

Hyundai’s double strategy

The company’s popular ‘One Drug, Two Tracks’ strategy is all about utilising one drug ‘Xafty’ to aim on other particular areas to assess the difference, need and appropriate treatment for the same. Xafty will focus on dengue fever in the Vietnam region, and in the US, it will fix its focus on the Upper-Respiratory Infection Viruses. This strategy might bring this condition closer to a solution door.

This idea shows the power of the drug, illustrating its proficiency to cure respiratory viral infections and mosquito-borne diseases. This drug is listed under the advanced antibiotics that have the potential to treat dual bacterial types with just one drug. Hyundai's appreciative strategy is a boon to its internal and external development.

CEO of Hyundai Bioscience USA, Mr Jason Kim, said, “During the presentation, we declared that our strategy engineered with Dr Smith is properly linked and complements to best address the unmet needs of the U.S. healthcare sector. We’re done with the preparation, now ready to submit our IND application to the FDA soon.”